JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 2
DOI:10.33266/1024-6177-2025-70-2-113-118
P.V. Sychev1, Yu.D. Udalov1, 2
Results of Evaluation of Four Cycles of Radionuclide Therapy with a Domestic Radiopharmaceutical Based on Radium-223 Chloride for the Treatment of Bone Metastases
1 Federal Scientific Clinical Center for Medical Radiology and Oncology, Dimitrovgrad, Russia
2 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Petr Vladimirovich Sychev, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: The evaluation of the efficacy and safety of a domestic radiopharmaceutical drug based on Radium-223 chloride in patients with bone metastases in comparison with the original drug.
Material and methods: In the period from 2022 to 2023, a study was conducted that included 36 patients diagnosed with metastatic castration–resistant prostate cancer in the absence of visceral metastases, who underwent planar osteoscintigraphy in the whole body mode and PET/CT with 18F-PSMA. In all patients included in the study, the fact of metastatic skeletal lesions and the absence of visceral metastases were confirmed by diagnostic studies before inclusion in the study. The effectiveness was assessed by comparing the data of planar osteoscintigraphy and PET/CT before the start of treatment and after cycle 4, as well as by assessing the pain syndrome. The safety of the drug was monitored by assessing hematological toxicity in dynamics before and after each cycle. In the study group, 22 patients (84.6 %), and in the control group, 14 patients (93.3 %) received 4 cycles of treatment. The fatal outcome was found in the research group in 3 people (11.5 %), in the control group in 1 patient (6.7 %) with a diagnosis of Covid-19. The general condition of the patients at the time of the fourth treatment cycle was satisfactory, there were no side effects in the form of redness at the injection site, nausea and vomiting.
Results: There was a deviation from the lower limits of normal in the study group in terms of hemoglobin level in 9 patients (35 %), in the control group in 6 patients (40 %), in neutrophil levels in 1 patient in the study group (3.8 %), in platelet level in 6 patients in the study group (23 %), in 5 patients in the control group (33.3 %), in the level of lymphocytes in 6 patients in the study group (23 %), which is associated with the underlying disease. The minimum values of the indicators did not require correction.
Conclusions: The first results of therapy with a domestic drug based on radium-223 chloride are comparable with the original drug.
Keywords: castration-resistant prostate cancer (CRPC), bone metastases, radionuclide therapy, radium-223 chloride, single-photon emission computed tomography, positron emission tomography
For citation: Sychev PV, Udalov YuD. Results of Evaluation of Four Cycles of Radionuclide Therapy with a Domestic Radiopharmaceutical Based on Radium-223 Chloride for the Treatment of Bone Metastases. Medical Radiology and Radiation Safety. 2025;70(2):113–118. (In Russian). DOI:10.33266/1024-6177-2025-70-2-113-118
References
1. Lowrance W.T., Murad M.H., Oh W.K., Jarrard D.F., Resnick M.J., Cookson M.S. Castration-Resistant Prostate Cancer. AUA Guideline Amendment. J Urol. 2018 Dec;200;6:1264-1272. doi: 10.1016/j.juro.2018.07.090. Epub 2018 Aug 4. PMID: 30086276.
2. Yau V., Chow E., Davis L., et al. Pain Management in Cancer Patients with Bone Metastases Remains a Challenge. J Pain Symptom Manage. 2004;27:1-3.
3. Sartor O. Radiopharmaceutical and Chemotherapy Combinations in Metastatic Castrate-Resistant Prostate Cancer: a New Beginning? J Clin Oncol. 2009;27:2417-2418.
4. Bruland O.S., Nilsson S., Fisher D.R., et al. High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the Alpha-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities. Clin Cancer Res. 2006;12:6250s-6257s.
5. Henriksen G., Breistol K., Bruland O.S., et al. Significant Antitumor Effect from Bone-Seeking, Alpha-Particle-Emitting (223)Ra Demonstrated in an Experimental Skeletal Metastases Model. Cancer Res. 2002;62:3120-3125.
6. Saad F., Carles J., Gillessen S., Heidenreich A., Heinrich D., Gratt J., Lévy J., Miller K., Nilsson S., Petrenciuc O., Tucci M., Wirth M., Federhofer J., O’Sullivan J.M. Radium-223 International Early Access Program Investigators. Radium-223 and Concomitant Therapies in Patients with Metastatic Castration-Resistant Prostate Cancer: an International, Early Access, Open-Label, Single-Arm Phase 3b trial. Lancet Oncol. 2016 Sep;17;9:1306-16. doi: 10.1016/S1470-2045(16)30173-5.
7. Parker C., Nilsson S., Heinrich D., Helle S.I., O’Sullivan J.M., Fosså S.D., Chodacki A., Wiechno P., Logue J., Seke M., Widmark A., Johannessen D.C., Hoskin P., Bottomley D., James N.D., Solberg A., Syndikus I., Kliment J., Wedel S., Boehmer S., Dall’Oglio M., Franzén L., Coleman R., Vogelzang N.J., O’Bryan-Tear C.G., Staudacher K., Garcia-Vargas J., Shan M., Bruland Ø.S., Sartor O. ALSYMPCA Investigators. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013 Jul 18;369;3:213-23. doi: 10.1056/NEJMoa1213755.
8. Shore N., Higano C.S., George D.J., et al. Concurrent or Layered Treatment with Radium-223 and Enzalutamide or Abiraterone/Prednisone: Real-World Clinical Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer. Prostate Cancer Prostatic. 2020;23:680–688. doi: 10.1038/s41391-020-0236-0.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.12.2024. Accepted for publication: 25.01.2025.